Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

Schweighofer, Carmen; Tuchscherer, Armin; Sperka, Sabine; Meyer, Thorsten; Rattel, Benno; Stein, Sandra; Ismail, Semra; Elter, Thomas; Staib, Peter; Reiser, Marcel; Hallek, Michael
December 2012
Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2367
Academic Journal
1D09C3 is a human monoclonal IgG4-type antibody against human leukocyte antigen-DR (HLA-DR) which has demonstrated pro-apoptotic activity against lymphoid tumors in vitro and in vivo. We report results from a phase I dose-escalation study which aimed to identify tolerated dosing, and the pharmacokinetic and pharmacodynamic profile of 1D09C3. Fourteen patients with relapsed/refractory B cell type leukemia/lymphoma were treated and followed after up to 4 weekly infusions of 1D09C3, administered in 6 dose levels at 0.25-8 mg/kg/day. Treatment was tolerated well with mostly mild side effects. The most common grade III-IV toxicities were hematological events observed in 4 patients. In one patient, treated at 8.0 mg/kg/day, a dose limiting toxicity occurred, identified as an invasive catheter-related infection. Adverse events resolved completely without long-term sequelae. 1D09C3 reduced peripheral blood B cells and monocytes by a median of 73-81 % in all patients, with a nadir reached 30-60 min after infusion and sustained for <96 h. Granulocytes and natural killer cells predominantly increased with variable time courses. Pharmacokinetic assessments showed detectable drug concentrations at doses 4-8 mg/kg/day and a terminal half-life of 0.7-7.9 h. Effective saturation of HLA-DR on peripheral blood B cells/monocytes was achieved, varying consistently with available serum concentrations and the cell-reducing activity of 1D09C3. In summary, 1D09C3 could be administered safely in patients with advanced B cell malignancies. Pharmacodynamic studies demonstrated a strong dose dependent but transient reduction of peripheral blood B cells and monocytes, consistent with a short drug serum availability.


Related Articles

  • Fatal infusion reaction with ARZERRA in Canada.  // Reactions Weekly;Aug2014, Vol. 1515 Issue 1, p2 

    The article reports on the letter issued by pharmaceutical company GlaxoSmithKline (GSK) and Health Canada about the occurrence of fatal infusion reaction in a patient with chronic lymphocytic leukaemia (CLL) who received intravenous ofatumumab (ARZERRA) therapy.

  • Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Perumal, Jai S; Foo, Farng; Cook, Perry; Khan, Omar // Multiple Sclerosis Journal;Aug2012, Vol. 18 Issue 8, p1197 

    Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines...

  • HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic... Michallet, Mauricette; Archimbaud, Eric // Annals of Internal Medicine;1/31/96, Vol. 124 Issue 3, p311 

    Characterizes the outcomes of HLA-identical sibling bone marrow transplantation for chronic lymphocytic leukemia (CLL) in patients younger than 60 years old. Pretransplant conditioning; Prophylaxis for graft-versus-host disease; Hematologic remission of half of the patient group; Feasibility of...

  • Rituximab: A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Keating, Gillian M. // Drugs;2010, Vol. 70 Issue 11, p1445 

    Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukaemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. The addition of...

  • Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia. Stagno, Fabio; Vigneri, Paolo; Del Fabro, Vittorio; Fidilio, Anna; Spina, Paolo; Massimino, Michele; Messina, Angelo; Di Raimondo, Francesco // Acta Haematologica;Oct2010, Vol. 124 Issue 2, p103 

    The article discusses a case of an elderly man with refractory B cell chronic lymphocytic leukemia (B-CLL) that was not treated by dasatinib (DAS). Before the patient started receiving DAS, he was given 5 other lines of treatment for his hematological disease, which include chlorambucil and...

  • Obinutuzumab Injection.  // AHFS Consumer Medication Information;Feb2020, p1 

    Obinutuzumab injection is used with chlorambucil (Leukeran) to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Obinutuzumab injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells.

  • Ofatumumab Injection.  // AHFS Consumer Medication Information;Feb2020, p1 

    Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells) in adults who have not gotten better after treatment with fludarabine (Fludara) and alemtuzumab (Campath). Ofatumumab injection is in a class of medications called monoclonal...

  • Rituximab for the Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. Hagemeister, Fredrick // Drugs;2010, Vol. 70 Issue 3, p261 

    Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-cell-derived haematological malignancies. Rituximab, in combination with chemotherapy, has significantly improved survival outcomes for patients diagnosed with follicular lymphoma (FL) and diffuse large...

  • Proteasome inhibition enhances HLA-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Stockmeyer, B.; Gramatzki, M.; Repp, R. // Cancer Cell International;2004 Supplement 1, Vol. 4, pS21 

    The article shows that proteasome inhibition enhances human leukocyte antigen (HLA)-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Although polymorphonuclear granulocytes (PMN) mediated significant lysis with HLA-class-II mAb, no significant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics